Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactulose and Rifaximin with Vegetable Diet for Post-TIPS Hepatic Encephalopathy
NCT02931123Phase 2Unknown
- Sponsor
- Sapienza University of Rome
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lactulose and rifaximin in hepatic encephalopathy (HE), sponsored by Sapienza University of Rome. Primary endpoint: Incidence of hepatic encephalopathy at 1 month. Status: unknown.
02
Drugs
lactuloserifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT02931123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931123.